skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Datamonitor Healthcare attended the annual meeting of the European Association for the Study of Diabetes (EASD), which took place in Barcelona, Spain, from 23 to 27 September 2013.

European Association for the Study of Diabetes (EASD) White paper

A large number of clinical trial results were presented at this year’s conference and Datamonitor Healthcare talks about the following:

 

  • SAVOR-TIMI 53/EXAMINE: DPP-IV inhibitors Onglyza (saxagliptin; Bristol-Myers Squibb/AstraZeneca) and Nesina (alogliptin; Takeda).
  • HARMONY: Albiglutide’s (GlaxoSmithKline) efficacy and how it compares to GLP-1 agonists, Victoza (liraglutide; Novo Nordisk), Bydureon (exenatide LAR; Bristol-Myers Squibb/AstraZeneca) and dulaglutide (Eli Lilly).
  • AWARD: Results and sales forecasts for GLP-1 agonist dulaglutide  and how its sales predictions compare to Victoza’s by 2018.
EASD 2013

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: